



Mylan – Recall of alprazolam

- On October 23, 2019, [Mylan announced](#) a consumer-level recall of one batch of [alprazolam](#) 0.5 mg tablets due to the remote potential for foreign material on the tablets.
- The recalled lot was distributed between July 2019 and August 2019.

Product Description	NDC#	Lot #
Alprazolam 0.5 mg tablets, 500 count bottle	0378-4003-05	8082708

- Alprazolam tablets are indicated for the management of anxiety disorder, the short-term relief of symptoms of anxiety, and for the treatment of panic disorder, with or without agoraphobia.
- Clinical impact from the foreign material, if present, is expected to be rare, but the remote risk of infection to a patient cannot be ruled out.
- Mylan has not received any reports of adverse events, to date, for the recalled lot.
- Patients should contact their physician or healthcare provider if they have experienced any problems that may be related to using the recalled alprazolam.
- Anyone with an existing inventory of the recalled product should quarantine and discontinue distribution of the product immediately.
- Contact Stericycle (appointed company for Mylan) at **1-888-843-0255** for further information regarding this recall.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2019 Optum, Inc. All rights reserved.